jnccn.org/abstract/journals/jnccn/16/12/article-p1429.xml

Preview meta tags from the jnccn.org website.

Linked Hostnames

14

Thumbnail

Search Engine Appearance

Google

https://jnccn.org/abstract/journals/jnccn/16/12/article-p1429.xml

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018

The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E–mutated anaplastic thyroid carcinoma.



Bing

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018

https://jnccn.org/abstract/journals/jnccn/16/12/article-p1429.xml

The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E–mutated anaplastic thyroid carcinoma.



DuckDuckGo

https://jnccn.org/abstract/journals/jnccn/16/12/article-p1429.xml

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018

The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E–mutated anaplastic thyroid carcinoma.

  • General Meta Tags

    87
    • title
      NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018 in: Journal of the National Comprehensive Cancer Network Volume 16 Issue 12 (2018)
    • Content-Type
      text/html; charset=utf-8
    • description
      The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E–mutated anaplastic thyroid carcinoma.
    • article:author
      Robert I. Haddad
    • article:author
      Christian Nasr
  • Open Graph Meta Tags

    7
    • og:url
      https://jnccn.org/view/journals/jnccn/16/12/article-p1429.xml
    • og:site_name
      JNCCN
    • og:type
      article
    • og:title
      NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018
    • og:description
      The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E–mutated anaplastic thyroid carcinoma.
  • Twitter Meta Tags

    4
    • twitter:card
      summary_large_image
    • twitter:site
      @jnccn
    • twitter:title
      NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018
    • twitter:description
      The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E–mutated anaplastic thyroid carcinoma.
  • Link Tags

    15
    • alternate
      /newsrss
    • canonical
      https://jnccn.org/view/journals/jnccn/16/12/article-p1429.xml
    • dns-prefetch
      //ajax.googleapis.com
    • preconnect
      //ajax.googleapis.com
    • preconnect
      //ajax.googleapis.com

Emails

2
  • [email protected]
  • ?subject=Link%20to%20NCCN%20Guidelines%20Insights%3A%20Thyroid%20Carcinoma%2C%20Version%202.2018&body=https%3A%2F%2Fjnccn.org%2Fview%2Fjournals%2Fjnccn%2F16%2F12%2Farticle-p1429.xml

Links

482